JLK, 'JLK-CTP Utilization Clinical Research Paper' Published in Prestigious International Journal

JLK (CEO Dongmin Kim), the first medical AI listed company, announced on the 8th that a clinical research paper utilizing its brain CT perfusion imaging analysis solution (JLK-CTP) has been published in an international academic journal.

The paper was published in the Annals of Neurology, a globally prestigious international journal with a 5-year impact factor of 9.9 and the official journal of the American Neurological Association. At a time when the JLK-CTP solution has obtained approval from the US FDA and Japan PMDA and is negotiating sales contracts with local distributors, this paper is regarded as an important study demonstrating the high reliability and efficacy of the JLK-CTP solution.

In Korea, approximately 110,000 cases of acute cerebral infarction occur annually, and the only currently recognized definitive treatment is drug therapy or procedures for vascular recanalization. CT perfusion imaging is primarily performed before procedures to evaluate complications from the procedure and the benefits of treatment.

JLK-CTP is a solution that visualizes irreversible regions and areas of reduced cerebral perfusion based on brain blood flow analysis results from brain CT perfusion images and automatically calculates the corresponding volumes.

In this study conducted over 15 years on patients who successfully underwent vascular recanalization procedures at Bundang Seoul National University Hospital, the optimal cerebral blood flow threshold to estimate the infarct core varied depending on the timing of MRI imaging, which serves as the reference for the final infarct volume. Additionally, the increase in infarct size after vascular recanalization showed significant variation among patients.

This suggests that the optimal cerebral blood flow threshold may differ according to the patient's clinical situation, indicating the need for further research on the current cerebral infarction treatment approach, which decides treatment policies based on fixed thresholds.

Furthermore, this study also utilized the JBS-01K (JLK-DWI) solution, which accurately measures infarct volume on MRI, enhancing the reliability of the analysis. It also demonstrated that JLK's quantitative analysis solutions can be effectively used in clinical research involving large-scale patient datasets.

Professor Beomjun Kim, the corresponding author of this study from the Department of Neurology at Bundang Seoul National University Hospital, stated, "Through this study, we confirmed that a domestic solution with technology comparable to the globally influential US Rapid AI can enable patient-tailored approaches in deciding cerebral infarction treatment policies according to clinical situations."

He added, "Considering the importance of procedures for cerebral infarction patients, various approaches suitable for clinical situations are needed rather than a fixed simple approach. We will collaborate with JLK to develop evidence and technology for optimal treatment policy decisions and strive to become a global leading group."

Dongmin Kim, CEO of JLK, emphasized, "With the publication of the JLK-CTP paper in a world-class academic journal, we will do our best to widely promote the excellence of JLK AI solutions and enhance the influence of JLK solutions in both domestic and overseas markets."